natgillin/translations-raw huggingface dataset:
The method of any one of the items 3 to 7, wherein thermal stability, refolding, expression yield, aggregation and/or binding activity of the immunobinder is not adversely affected by the mutating. 
Postupak prema bilo kojem od zahtjeva 3 do 7, naznačen time, da _nema štetnog utjecaja na toplinsku stabilnost, ponovno savijanje, doprinos ekspresije, agregaciju i/ili na aktivitet vezanja za imunovezno sredstvo prilikom mutacije.
A pharmaceutical formulation for use in the treatment of respiratory disease according to Claim 1 wherein Compound (I) is administered by inhalation at a dose of 25 µg per day, calculated as the free base. 
Farmaceutska formulacija namijenjena upotrebi u liječenju bolesti dišnog sustava u skladu s patentnim zahtjevom 1, naznačena time što se Spoj (1) primjenjuje inhalacijom u dozi od 25 ug dnevno, izračunatoj kao slobodna baza.
The method of claim 26, wherein if the determination of no improvement is made in step (d), the therapeutically effective amount of the composition is increased. 
dC ili dT, namijenjeni upotrebi u skladu s patentnim zahtjevom 18, naznačeni time što ako se u koraku (d) odredi da nema poboljšavanja, terapijski djelotvornu količinu pripravka se povećava.
wherein R2 and R3 are independently selected from the group consisting of H, (C1-C6)-alkyl, wherein alkyl is linear-chain or branched, (C1-C6)-alkenyl, wherein alkenyl is linear-chain or branched and contains one to three double bonds, aryl, in particular C6-C12-aryl, carboxyl, or (C1-C4)-carboxyalkyl, in particular also cycloalkyl, e.g., C3-C8-cycloalkyl, is oxidized. 
R. H pri čemu su R> i R3 neovisno odabrani iz skupine koja se sastoji od H, (C,-C4) - alkila, pri čemu jo alkil linearni ili razgranani lanac, (C,-Cg)-alkenil, pri čemu je alkenil linearni ili razgranani lanac i sadržava jednu do tri dvostruke veze, aril, osobito Cg-Cp-aril, karboksil, ili (C;-C,)-karboksialkil, osobito također cikloalkil, osobito C3-Cg-cikloalkil, se oksidira.
The pharmaceutical composition of claim 8, the use of claim 9, 19 or 22 or the vaccine of claim 19 or 21, wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, endometriosis, esophageal cancer, gastric cancer, diffused type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 6, ili peptid ili polinukleotid u skladu s patentnim zahtjevom 15, naznačen time što se rak bira iz skupine koju čine rak mokraćnog mjehura, rak dojke, rak vrata maternice, kolangiocelularni karcinom, CML, kolorektalni rak, endometrioza, rak jednjaka, rak želuca, rak želuca difuznog tipa, rak jetre, NSCLC, limfom, osteosarkom, rak jajnika, gušterače rak, rak prostate, bubrežni karcinom, SCLC, tumor mekog tkiva i tumor na testisima.
The internal temperature was increased to 25 °C from 14 °C. The resulting solution was aged at 22 - 25 °C for 60 min. 
Interna temperatura je povećana na 25*C od 14 "C, Rezultirajuća otopina je odstajala na 22-25*C tijekom 60 min.
The coupling system according to claim 1, wherein the receiving space extends over a circumferential angle of approx. 270°, and wherein the first and second access space end in two surfaces disposed at approximately right angles to each other on the outside of the respective base body. 
(22) pruža po obodnom kutu od otprilike 270", te što se odgovarajući prvi i drugi pristupni prostor (27, 28) u dvije površine međusobno nalaze pod otprilike pravim kutem na vanjskoj strani odgovarajućeg osnovnog tijela (21), gdje je jedna od tih površina zaustavna površina (26).
A compound or a pharmaceutically acceptable salt thereof of any one of claims 1 to 12 for use in treating an immune response disorder or vascular cell proliferation disorder. 
Spoj ili njegova farmaceutski prihvatljiva sol iz bilo kojeg od zahtjeva 1 do 10, naznačen time, što se koristi za liječenje poremećaja imunog odgovora ili poremećaja proliferacije vaskularnih stanica.
The method of claim 16, wherein the molecule is a plasmid encoding a chimeric antigen receptor comprising an extracellular antigen-binding domain that specifically binds to a target antigen, a transmembrane domain, and an intracellular signaling domain, optionally wherein the target antigen is a cancer-associated antigen and/or i) the complex or nanoparticle further comprises an siRNA; or ii) the method further comprises contacting the cell with a complex according to claim 5 or 7 or a nanoparticle according to any one of claims 6-9, wherein the complex or nanoparticle comprises an siRNA; or 
Metoda prema patentnom zahtjevu 16, pri čemu je a) molekula je plazmid koji kodira himerni antigenski receptor, koji sadrži izvanstaničnu domenu vezanja antigena, koja se specifično veže na ciljm antigen, transmembransku domenu i unutarstaničnu signalnu domenu, opcijski je ciljni antigen antigen povezan na karcinom i/ili 1) kompleksni spoj ili nanočestica nadalje sadrži siRNK; ili 11) metoda nadalje obuhvaća kontakt stanice s kompleksnim spojem prema patentnom zahtjevu 5 ili 7 ili nanočesticu prema bilo kojem od patentnih zahtjeva 6-9, pri čemu kompleksni spoj ili nanočestica sadrži siRNK; ili b) ilije molekula siRNK.
These many differences between the small intestine and the large intestine explain the distinctive nature of some pathologies which occur at the expense of the large intestine and in particular the colon. 
Ove razlike između tankog i debelog crijeva objašnjavaju i različitu prirodu nekih patoloških stanja koja se događaju nauštrb debelog crijeva te posebno u predjelu kolona.
However, no indication exists for the possible use of said compounds for the treatment of platelet activation; thrombosis; stroke; tissue damage due to ischemic and/or to ischemia/reperfusion; pathological conditions where oxidative stress plays an important role in their pathogenesis; and/or atherosclerosis. 
Međutim, ne postoji nijedna indikacija za moguću upotrebu spomenutih spojeva za liječenje aktivacije trombocita; tromboze; udara kapi; ozljede tkiva zbog ishemije i/ili ishemije/reperfuzije; patoloških stanja za čiju patogenezu ima važnu ulogu oksidativan stres; i/ili ateroskleroze.
The microcarrier may for example be coated with a material selected from the group consisting of glass (e.g., SoloHill's glass-coated microcarriers), N,N-diethylaminoethyl (e.g., Cytodex®1, Amersham), collagen (e.g., Cytodex®3, Amersham) and recombinant proteins (e.g., ProNectin®, SoloHill). 
Mikronosač može, primjerice biti omotan s materijalom koji je izabran iz skupine koja obuhvaća staklo (primjerice, SoloHill-ovi mikronosači omotani staklom), N,N-dietilaminoetil (primjerice, Cytodex 1, Amersham), kolagen (primjerice, Cytodex 3, Amersham) te rekombinantne proteine (primjerice, ProNectin, SoloHuill).
and R8 each independently represent a hydrogen atom, a C1-C4 haloalkyl group, a C1-C4 hydroxyalkyl group or a linear or branched C1-C4 alkyl group, which alkyl group is unsubstituted or substituted by one or more substituents selected from a C1-C4 alkoxy group, a cyano group or a C3-C4 cycloalkyl group; 
i R8 svaki zasebno predstavljaju atom vodika, C1-C4 haloalkilnu grupu, C1-C4 hidroksialkilnu grupu ili linearnu ili razgranatu C1-C4 alkilnu grupu, pri čemu je alkilna grupa nesupstituirana ili supstituirana s jednim ili više supstituenata odabranih iz C1-C4 alkoksi grupe, cijano grupe ili C3-C4 cikloalkilne grupe;
A dose counter as claimed in claim 9, wherein the means for preventing reverse rotation comprises at least one pawl arranged to engage the ratchet teeth of the gear wheel. 
Brojač doze u skladu s patentnim zahtjevom 10, pri čemu sredstvo za sprečevanje reverzne rotacije obuhvaća najmanje jedan zapinjač postavljen za prihvaćanje zapornog zuba nazubljenog kotača (130).
According to the process disclosed in Hungarian patent specification No. 
Sukladno procesu koji je opisan u mađarskoj patentnoj specifikaciji br.
The method of claim 9, further comprising the step of administering simultaneously or sequentially to the subject in need thereof at least one other anti-inflammatory agent, immunosuppressive agent, steroid, non-steroidal anti-inflammatory agent, or a mixture thereof. 
Spoj sukladno patentnom zahtjevu 17, koje još obuhvaća najmanje jedan drugi anti-kancerogeni agens, anti-upalnih agens, imunosupresivni agens, steroid, ne-steroidni anti-upalni agens, antihistamin, analgetik, ili njihovu mješavinu.
It has been suggested in the art to apply a protective coating onto a fabric made of fibers or threads made of fibers. 
Termoplastična tkanina izrađena od vlakana otpornih na toplinu ili izrađena od niti vlakana otpornih na toplinu, impregnirana pripravkom koji sadrži smjesu proizvoda A i proizvoda B:
A compound of claim 1, wherein the fused six membered ring having vertices a, b, c and d is a fused pyridine ring, a fused pyrimidine ring, or an N-oxide thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je kondenzirani šesteročlani prsten koji ima vrhove a, b, c i d kondenzirani piridinski prsten, kondenzirani pirimidinski prsten ili njihov N-oksid.
a DSC peak with a Tonset at 97° C.±2° C. measured with a heating rate of 10°/min; and a melting point of 97° C.±2° C. wherein the disease is selected from the group consisting of Parkinson's Disease, Parkinson's plus syndrome, depression, fibromyalgia and restless-legs syndrome. 
Polimorfni oblik Rotigotina kako je definirano u bilo kojem od patentnih zahtjeva 1-2 ili Rotigotin ljekovita supstanca prema zahtjevima 3-6 za upotrebu u postupku liječenja pacijenta koji pati od poremećaja povezanih sa dopaminom, gdje je spomenuti poremećaj odabran od Parkinsonove Bolesti Parkinsonovog plus sindroma, depresije, fibromijalgije i/ili sindroma nemirnih nogu.
providing a second web (172) having a series of parallel grooves with a three-sided polygonal cross section; and, 
osiguravanje druge mreže (172) s nizom paralelnih žljebova s poligonalnim trostranim poprečnim presjekom; i
A process for making a compound of formula (II), comprising the following step: wherein X, Y, Ra, PG1 and PG2 are as defined in claim 1. 
Postupak za pripremu spoja formule (II), koji sadrži sljedeći korak:
is -COOR5 (wherein R5 is a hydrogen atom or a carboxyl protecting group) or-C(O)N(R6)SO2R7 (wherein R6 is a hydrogen atom or an imino protecting group; and R7 is an optionally substituted C1-6 alkyl group or an optionally substituted C3-8 cycloalkyl group); is a hydrogen atom or an imino protecting group; and 
je -COOR5 (pri čemu je R5 atom vodika ili karboksilna zaštitna skupina) ili -C(O)N(R6)SO2R7 (pri čemu R6 je atom vodika, ar-C1-6 alkilna skupina, C1-6 alkoksi-C1-6 alkilna skupina, acilna skupina, C1-6 alkoksikarbonilna skupina, ar-C1-6 alkoksikarbonilna skupina, ariloksikarbonilna skupina, C1-6 alkilsulfonilna skupina, arilsulfonilna skupina ili silil skupina; i R7 je po izboru supstituirana C1-6 alkilna skupina ili po izboru supstituirana C3-8 cikloalkilna skupina);
Value Cutoff signal peptide? 
Prethiđanja prekida za MB9549 signalni peptid
In another preferred embodiment, R2 represents H or alkyl, more preferably methyl. 
Sastav prema zahtjevu 1 ili 2 naznačen time da R> je H ili alkil.
The hydrolysis was slowest in monkey and human homogenates, with less than 3% of the total compound converted to gemcitabine in a 6 hour incubation. 
Hidroliza je najsporija kod majmunskih i ljudskih homogenata, uz manje od 3 % od ukupnog spoja prevedenog u gemcitabin tijekom inkubacije od 6 sati.
Thereby, the cutting direction is transverse to the wood fibers. 
Na taj način smjer rezanja je popreko na vlakna drva.
represents the substituted imidazol-5-yl of Formula (II) wherein: 
R3 predstavlja supstituirani imidazol-5-il formule (ID)
A pharmaceutical or diagnostic composition containing at least one IL-6 antibody or fragment according to any one of claims 1 or 2 and a pharmaceutically acceptable carrier. 
Farmaceutski ili dijagnostički sastav koji sadrži najmanje jedno anti-IL-6 protutijelo sukladno bilo kojem od patentnih zahtjeva 1-3 1 farmaceutski prihvatljivi nosač.
Air-drying is normally considered to be a rather slow curing process not suitable for industrial coatings where a high processing rate is of importance. 
Smatra se da je sušenje zrakom normalno sporiji proces umreživanja, koji nije prikladan za industrijsko prevlačenje gdje je važna velika brzina obrade.
a pair of bearing portions (10), and 
- > par nosećih dijelova (10), 1 -
A humanized monoclonal antibody that binds to STEAP-1, wherein the antibody comprises a heavy chain (HC) comprising: 
(i) humanizirano monoklonalno protutijelo koje se veže na STEAP-I, pri čemu protutijelo ima jaki lanac (HC) koji obuhvaća:
In a preferred embodiment, the conjugated nucleic acid molecule has one of the following formulae: 
PATENTNI ZAHTJEVI 1. - Konjugirana molekula nukleinske kiseline, naznačena time što ima sljedeću formulu:
patients having a Mini-Mental State Examination score of less than or equal to MMSE 24,25,26,27,28 or 29; and 
Mini-Mental State Examination) manje ili jednako 24, 25, 26, 27, 28 ili 29;1
In aqueous solutions its rheologic properties are highly dependent upon the size of the molecule; e. g. in 1% aqueous solution HA of the 1000 kDa molecular size has 3000 mPa viscosity, whereas HA of the 4000 kDa molecular size has 400000 mPa viscosity in similar concentration (H. B. Wik and O. Wik: Rheology of Hialuronan, The Chemistry, Biology and Medical Applications of Hialuronan and its Derivatives (ed. 
U vodenim otopinama njegove reološke karakteristike su jako ovisne od veličine molekule; tj. 1% vodene otopine HA od 1000 kDa molekularne veličine ima viskoznost od 3000 mPa, gdje HA od 4000 kDa molekularne veličine ima viskoznost od 400000 mPa u sličnim koncentracijama (H. B. Wik i O. Wik: reologija hijaluronana, Kemizam, biologija i medicinska primjena hijaluronana i njegovih derivata - The Chemistry, Biology i Medical Application of Hialuronana and its Derivates (ed.
The anti-LAG-3 antibody and/or the anti-PD-1 antibody for use according to any one of claims 1-13, wherein the treatment comprises administration of the anti-PD-1 antibody prior to administration of the anti-LAG-3 antibody. 
Anti-LAG-3 antitijelo i/ili anti-PD-1 antitijelo za primjenu u skladu sa bilo kojim od patentnih zahtjeva 1-10, gdje liječenje obuhvaća administraciju anti-PD-1 antitijela prije administracije anti-LAG-3 antitijela.
For example a pharmaceutical composition which comprises 50 mg of the preferred venlafaxine hydrochloride, which has a molar mass of 330.87 g/mol, would be regarded as 41.92 mg of venlafaxine, which has a molar mass of 277.40 g/mol. 
Kao primjer, farmaceutski pripravak koji sadrži 50 mg poželjnog venlafaksin-hidroklorida, molarne mase 330,87 g/mol, bi se gledalo kao 41,92 mg venlafaksina, molarne mase 277,40 g/mol. HR P20080007 T3
The 5-fluorouracil derivative or a salt thereof according to claim 1, wherein the group represented by the following formula in Formula (I) is: a group represented by: wherein R1 represents a hydrogen atom, an allyl group, or a substituted or unsubstituted benzyl group; a group represented by: a group represented by: wherein R1 represents a hydrogen atom, an allyl group, or a substituted or unsubstituted benzyl group; or a group represented by: 
skupina koja je predstavljena sa: [image] skupina koja je predstavljena sa: [image] u kojoj R1 predstavlja atom vodika, alil-skupinu, ili benzil-skupinu koja je nesupstituirana ili je supstituirana s jednim do pet supstituenata odabranih iz skupine koju čine: ravnolančana ili razgranata C1-6-alkil-skupina, ravnolančana ili razgranata C1-6-alkoksi-skupina, atom halogena, nitro-skupina i cijano-skupina; ili skupina koja je predstavljena sa:
The anti-VEGF antagonist antibody and/or anti-alpha5beta1 antagonist antibody for use according to claim 7, wherein the cancer is selected from the group consisting of breast cancer, cervical cancer, colorectal cancer, lung cancer, non-Hodgkins lymphoma (NHL), renal cell cancer, prostate cancer, liver cancer, head and neck cancer, melanoma, ovarian cancer, mesothelioma, soft tissue cancer, and multiple myeloma. 
Protutijelo antagonista anti-VEGF i/ili protutijelo antagonista anti-alfa5betal, za uporabu prema zahtjevu 7, naznačen/i time, da je rak odabran iz skupine koju čine: rak dojke, rak cerviksa, kolorektalni rak, rak pluća, non- Hodgkinsov limfom (NHL), rak renalnih stanica, rak prostate, rak jetre, rak glave i vrata, melanom, rak jajnika, mezoteliom, rak mekog tkiva i višestruki mijelom.
The oligomer of claim 1 or 9, wherein the oligomer has at least 90%, 96%, 97%, 98% or 99% sequence identity to Complement Component C6 sequence represented by SEQ ID NO:1. 
Oligomer prema zahtjevu 1 ili 9, naznačen time da oligomer ima najmanje 90%, 96%, 97%, 98% ili 99% sekvencijske identičnosti s KOMPLEMENTARNOM KOMPONENTOM C6 sekvence predstavljene SEQ ID NO:
A method for selecting a multiple sclerosis (MS) patient in need of heightened monitoring for development of a secondary autoimmune disease after lymphocyte depleting therapy, comprising: measuring the level of interleukin-21 (IL-21) in a blood sample from the MS patient; and comparing the level of IL-21 in the sample from the MS patient with the IL-21 level from a subject without an autoimmune disease, wherein elevated IL-21 in said patient compared to a subject without an autoimmune disease indicates that the patient is in need of heightened monitoring for development of a secondary autoimmune disease compared to MS patients without elevated IL-21. 
Postupak za odabir pacijenta s multiplom sklerozom (MS) kojem je potrebno pojačano praćenje razvoja sekundarne autoimune bolesti nakon terapije osiromašenja limfocita, comprising: mjerenje razine interleukin-21 (IL-21) u uzorku krvi od pacijenta koji ima MS; i usporedbu razine IL-21 u uzorku od pacijenta koji ima MS sa razinom IL-21 od subjekta bez autoimune bolesti, pri čemu povišena razina IL-21 kod navedenog pacijenta u usporedbi sa subjektom bez autoimune bolesti pokazuje da pacijent ima potrebu za pojačanim praćenjem razvoja sekundarne autoimune bolesti u usporedbi s MS pacijentima bez povišene razine IL-
On average 24-nor-ursodeoxycholic acid and/or pharmaceutical acceptable salts and esters thereof may preferably be administered to a patient in an amount of 25 mg to 5 g, preferably 100 mg to 2.5 g, in particular 800 mg to 1.5 g per day. However, 1 g of 24-nor-ursodeoxycholic acid and/or pharmaceutical acceptable salts and esters thereof is most preferably administered to a patient. 
Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, koje se upotrebljavaju za liječenje i/ili prevenciju hepatocelularnog karcinoma i kolangiokarcinoma, prema zahtjevima 1 ili 2, naznačene time, da se norursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, primjenjuju na pacijentu u dnevnoj količini od 25 mg do 5 g, poželjno od 100 mg do 2,5 g, posebno od 800 mg do 1,5 g.
The co-crystal of any one of claims 1-5, or a pharmaceutical composition of any one of claims 6-8, for use in treating cancer in a patient according to claim 10, further comprising administering an additional anticancer therapy; optionally wherein the additional anticancer therapy is an anticancer agent or radiation therapy, or both; optionally, wherein the anticancer agent is a chemotherapeutic agent; optionally, wherein the chemotherapeutic agent is etoposide, doxorubicin, daunorubicin, epirubicin or bleomycin. 
Sukristal u skladu s bilo kojim od patentnih zahtjeva 1-5, ili farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 6-8, namijenjeni upotrebi u liječenju raka kod pacijenta u skladu s patentnim zahtjevom 10, naznačeni time što dodatno uključuju primjenu dodatnu terapiju raka; gdje dodatna terapija raka može biti sredstvo protiv raka ili radioterapija, ili oboje; gdje sredstvo protiv raka može biti kemoterapijsko sredstvo; gdje kemoterapijsko sredstvo može biti etopozid, doksorubicin, daunorubicin, epirubicin ili bleomicin.
a T cell receptor a-chain comprising at least one, preferably two, more preferably all three of the CDR sequences of the T cell receptor a-chain of SEQ ID NO: x or a variant thereof, and 
(i) o-lanac T staničnog receptora koji sadrži sve tri CDR sekvence a-lanca T staničnog receptora od SEK ID BR: x,1
In a preferred embodiment there is provided a SIN-LV comprising an expression cassette containing from 5′ to 3′ end a CMV promoter the B-globin intron containing an RRE element in its sequence and the RD114-TR ORF. The present invention provides a method for producing LV comprising: 
Metoda prema zahtjevu 11 naznačena time da je RD114-TR integriran koristeći SIN lentivirusni vektor koji se sastoji od kazete za ekspresiju koja sadrži od 5 'do 3* kraja CMV promotora B- globinski intron s RRE elementom u svome slijedu 1ORF RD114-TR.
represents a 3- or 4-pyridine ring alternatively a 4- or 5-pyrimidine ring; the ring being optionally substituted by a C1-2 alkyl group, a C1-2 alkoxy group or a halogen atom; 
predstavlja 3- ili 4-piridinski prsten, ili 4- ili 5-pirimidinski prsten, gdje je navedeni prsten izborno supstituiran s C1-2 alkilnom skupinom, C1-2 alkoksi skupinom ili atomom halogena;
is Ser or absent; is X wherein X is selected from the group consisting of Glu, Lys, and Cys; and wherein the side chain of X is conjugated to a lipophilic substituent having the formula: 
X28 je odabran od Ser, Lys i Arg; gdje je X odabran iz skupine koju čine Glu, Lys i Cys; pri čemu je bočni lanac od najmanje jednog ostatka X konjugiran na lipofilni supstituent koji ima sljedeću formulu: (i) Z!', gdje Z! je lipofilni dio skupine konjugiran izravno na bočni lanac od X; ili
The composition of claim 17 wherein said B-cyclodextrin is a hydroxypropyl B-cyclodextrin or sulfobutylether B-cyclodextrin, said pharmaceutically acceptable salt is an acetate salt, and said pH adjusting agent is sodium bicarbonate. 
Sastav prema zahtjevu 11, naznačeno time da je spomenuti ciklodekstrin hidroksipropil B-ciklodekstrin ili sulfobutileter B-ciklodekstrin, a spomenuta farmaceutski prihvatljiva sol sol acetata, te spomenuti agens prilagodbe PH vrijednosti natrijev bikarbonat.
A compound according to any one of Claims 1 to 3 wherein R1 is pyrazol-4-yl optionally substituted with 1 to 3 methyl or ethyl groups; or a pharmaceutically acceptable salt thereof 
Spoj u skladu s bilo koji od patentnih zahtjeva 1 do 3, naznačen time što R1 je pirazol-4-il, izborno supstituiran s 1 do 3 metilne ili etilne skupine; ili njegova farmaceutski prihvatljiva sol.
The compounds according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and can be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. 
Spojevi prema pikazanom izumu mogu tako biti formulirani za parenteralnu primjenu (t.j. injekcijom, na primjer bolus injekcijom ili kontinuirano infuzijom) i mogu biti predstavljeni jediničnim dozirnim oblikom u ampulama, već napunjenim špricama, infuzijama malog volumena ili spremnicima višekratnih doza sa dodanim konzervansom.
The diabody of paragraph 16, wherein albumin-binding domain (ABD) of said streptococcal protein G is albumin-binding domain 3 (ABD3) of protein G of Streptococcus strain G148. 
Molekula diatijela prema zahtjevu 8, naznačena time što domena vezanja albumina (ABD) streptokoknog proteina G je albumin-vezujuća domena 3 (ABD3) proteina G soja Streptococcus G 148.
exposing the one or more plants to growth-promoting light; and looping back along the linear return path for repeating and advancing the plurality of cradles along the path until the one or more plants have reached a target growth for the machine. 
izlaganje jedne ili više biljaka tekućini za poticanje rasta; te ponavljanje napredovanja mnoštva kolijevki (14) duž staze (P) sve dok jedna ili više biljaka ne dostignu ciljani rast za stroj (10), naznačen time da ima orijentiranje kolijevki za uzgoj (14) na strmini;